Abstract 5535
Background
PIK3CA mutations occur in ≈ 40% of HR+/HER2− breast cancers. In the phase III SOLAR-1 study (NCT02437318), ALP (PI3Kα inhibitor) + FUL significantly prolonged progression-free survival vs placebo (PBO) + FUL in patients (pts) with HR+/HER2− ABC, prior endocrine therapy, and PIK3CA mutations (HR 0.65; P < 0.001; Andre F, et al. NEJM. 2019). We report pt management details of key AESIs from SOLAR-1.
Methods
Pts received ALP + FUL (n = 284) or PBO + FUL (n = 287). Safety was assessed per CTCAE v4.03 and regardless of PIK3CA mutation status. We evaluated time to onset and management of key AESIs in patients receiving ALP.
Results
The median ALP treatment exposure was 5.5 mo. As previously reported, the most common any-grade AESIs were hyperglycemia, diarrhea, and rash (Table). Rates of ALP discontinuation and median times to onset and improvement are presented in the table. Supportive medication was frequently used to manage hyperglycemia, diarrhea, and rash. In pts with anti-rash medication initiated prior to onset of rash (n = 86), 60 (69.8%) received antihistamines. Use of anti-rash medication prior to onset of rash was associated with decreased frequency of rash (26.7% vs 53.9% in the overall population) and decreased reported grade (grade 3, 11.6% vs 20.1%). During the study, the implementation of more detailed AE management guidelines decreased treatment discontinuation due to any-grade AEs (29.2% vs 20.7%) and grade ≥ 3 events (18.1% vs 7.9%) between the first 50% of pts randomized and the last 50% of patients randomized.Table:
324P
Hyperglycemia | Diarrheaa | Rash | |
---|---|---|---|
n = 284 | |||
Pts with any-grade event, n (%) | 187 (65.8) | 164 (57.7) | 153 (53.9) |
-ALP discontinuation due to event, n (%) | 19 (10.2) | 8 (4.9) | 12 (7.8) |
-Received supportive medication, n (%) | 163 (87.2) | 104 (63.4) | 134 (87.6) |
-Most-common supportive medication for any-grade event, n (%) | Metformin, 142 (87.1) | Antipropulsives, 69 (66.3) | Steroids, 113 (84.3)b,c |
Pts with ≥ grade-3 event, n (%) | 110 (38.7)d | 19 (6.7) | 28 (9.9)e |
-Time to onset, median (range), days | 15 (5-395)d | 139 (10-470) | 13 (9-571)e |
-Time to improvement by ≥ 1 grade, median (95% CI), days | 6 (4-7)d,f | 18 (9-45) | 11 (8-NE)e |
Based on preferred term.
bNote that this is for pts who already had developed rash, which is different from pts who received medication before the onset of rash.
cIncludes both topical and systemic.
dBased on fasting plasma glucose values.
eBased on single preferred term.
fRange.
Conclusions
Adverse events associatated with ALP were manageable, improved with appropriate intervention (medication and/or ALP dose interruptions/modifications), and were generally reversible upon treatment discontinuation. Use of anti-rash medication prior to rash onset reduced the frequency and grade of rash.
Clinical trial identification
NCT02437318.
Editorial acknowledgement
Tara Wabbersen of MediTech Media, LLC funded by Novartis.
Legal entity responsible for the study
Novartis.
Funding
Novartis Pharmaceuticals Corp.
Disclosure
H.S. Rugo: Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer Inc.; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck Sharp & Dohme Corp.; Research grant / Funding (institution): Novartis International AG; Research grant / Funding (institution), Travel / Accommodation / Expenses: Eli Lilly and Company; Research grant / Funding (institution): Genentech, Inc.; Research grant / Funding (institution): Oklahoma Blood Institute; Research grant / Funding (institution): Odonate Therapeutics, Inc.; Research grant / Funding (institution): Daiichi Sankyo Company, Limited; Travel / Accommodation / Expenses: Mylan N.V.; Travel / Accommodation / Expenses: Amgen Inc.; Travel / Accommodation / Expenses: Puma Biotechnology, Inc. F. André: Research grant / Funding (institution): Novartis International AG; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer Inc.; Research grant / Funding (institution): Eli Lilly and Company; Research grant / Funding (institution): F. Hoffmann-La Roche Ltd. T. Yamashita: Honoraria (self), Research grant / Funding (institution): Chugai Pharma USA, Inc; Honoraria (self): Eisai Inc.; Honoraria (self): Novartis International AG; Honoraria (self): Taiho Oncology, Inc.; Honoraria (self), Research grant / Funding (institution): Nippon Kayaku Co.,Ltd.; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Kyowa Hakko Kirin Co., Ltd.; Honoraria (self): Pfizer Inc. J. Cruz Jurado: Honoraria (self): Novartis International AG; Honoraria (self): Genentech, Inc.; Honoraria (self): Elsai; Honoraria (self): Ipsen; Honoraria (self): EMD Serono. D. Juric: Honoraria (self): Novartis International AG; Honoraria (self): Genentech, Inc.; Honoraria (self): Eisai Inc.; Honoraria (self): Ipsen Pharma; Honoraria (self): EMD Serono, Inc. I. Mayer: Honoraria (self), Research grant / Funding (institution): Novarts International AG; Research grant / Funding (institution): Genentech, Inc.; Research grant / Funding (institution): Pfizer, Inc.; Honoraria (self): Eli Lilly and Company; Honoraria (self): AstraZeneca; Honoraria (self): GlaxoSmithKline plc.; Honoraria (self): MacroGenics, Inc. E.M. Ciruelos: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis International AG; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: F. Hoffmann-La Roche Ltd; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer Inc. H. Iwata: Honoraria (self), Research grant / Funding (institution): Novartis International AG; Honoraria (self): F. Hoffmann-La Roche via Chugai; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer, Inc.; Honoraria (self): Eli Lilly and Company; Honoraria (self): Daiichi Sankyo Company, Ltd. P.F. Conte: Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis International AG; Speaker Bureau / Expert testimony, Research grant / Funding (institution): F. Hoffmann-La Roche Ltd; Speaker Bureau / Expert testimony: Genentech, Inc.; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution): EMD Serono, Inc.; Travel / Accommodation / Expenses: Celgene Corporation. M. Campone: Research grant / Funding (institution): Novartis International AG; Honoraria (self), Research grant / Funding (institution): F. Hoffmann-La Roche Ltd; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer, Inc.; Honoraria (institution): Servier Laboratories; Honoraria (institution): Sanofy; Honoraria (institution): Accord; Research grant / Funding (institution): Tessaro. C. Wilke: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. D. Mills: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis International AG. M. Miller: Shareholder / Stockholder / Stock options, Full / Part-time employment: Novartis. S. Loibl: Honoraria (institution): Novartis International AG; Honoraria (institution): Pfizer, Inc.; Honoraria (institution): Celgene Corporation; Honoraria (institution): Amgen; Honoraria (institution): F. Hoffmann-La Roche Ltd; Honoraria (institution): AstraZeneca; Honoraria (institution): Abbvie; Honoraria (institution): Eli Lilly and Company; Honoraria (institution): Daiichi Sankyo Company, Ltd; Honoraria (institution): Eirgenix. All other authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract